In vitro study | Ozenoxacin (OZN) shows potent antibacterial activities against clinical isolates of Gram-positive microorganisms, with MICs ranging from 0.008 to 4 mg/L. Ozenoxacin shows good activities against strains of MRSA, MSSA, MSSE, and MRSE with 2, 3, or 4 mutations in the gyrA and grlA (parC) genes. Ozenoxacin inhibits MSSA strains and S. agalactiae strains, with the rates of resistance of >10 −10 and 5.3 × 10 −10 , respectively. The maximum MIC value for mutant strains is 8 mg/L for ozenoxacin. |